2007
Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance
Seifer DB, MacLaughlin DT. Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance. Fertility And Sterility 2007, 88: 539-546. PMID: 17559842, DOI: 10.1016/j.fertnstert.2007.02.014.Peer-Reviewed Original ResearchConceptsPolycystic ovarian diseaseMullerian Inhibiting SubstanceOvarian reserveOvulation inductionInhibiting SubstanceDiagnosis of PCODRisk of OHSSOvarian growth factorsWidespread clinical useOvarian hyperstimulationOvarian diseaseOvarian functionMEDLINE reviewClinical significanceIntracycle variabilityEarly markerClinical useConventional markersDiagnostic markerGrowth factorSpecific cutIntercycle variabilityDifferent assaysMarkersDiagnosisSerum müllerian-inhibiting substance in Down's syndrome pregnancies
Seifer DB, MacLaughlin DT, Cuckle HS. Serum müllerian-inhibiting substance in Down's syndrome pregnancies. Human Reproduction 2007, 22: 1017-1020. PMID: 17218369, DOI: 10.1093/humrep/del497.Peer-Reviewed Original ResearchConceptsDown syndrome pregnanciesMüllerian-inhibiting substanceSyndrome pregnanciesUnaffected pregnanciesPregnancy-associated plasma proteinMI levelsMaternal serum levelsSerum MIS levelsWeeks of gestationCase-control studyAntenatal screening programmeAssisted reproduction techniquesMedian valueSerum levelsMIS levelsMaternal ageScreening programPregnancyDown syndromeUnaffected controlsReproduction techniquesSignificant correlationSyndromePlasma proteinsSerum
2005
Müllerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology
Silberstein T, MacLaughlin DT, Shai I, Trimarchi JR, Lambert-Messerlian G, Seifer DB, Keefe DL, Blazar AS. Müllerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology. Human Reproduction 2005, 21: 159-163. PMID: 16123085, DOI: 10.1093/humrep/dei270.Peer-Reviewed Original ResearchConceptsBasal FSH levelsOvarian reserveFSH levelsHCG administrationMIS levelsIVF outcomesOocyte qualityDay 3 FSH levelsMI levelsImproved oocyte qualityTime of hCGClinical pregnancy rateManagement of patientsSerum estradiol levelsHigher implantation rateEmbryo morphologyEmbryo morphology scoreNumber of oocytesEarly antral folliclesEnzyme-linked immunosorbentIVF cyclesOocyte retrievalPatient ageEstradiol levelsImplantation rateMetformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment
Fleming R, Harborne L, MacLaughlin DT, Ling D, Norman J, Sattar N, Seifer DB. Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertility And Sterility 2005, 83: 130-136. PMID: 15652898, DOI: 10.1016/j.fertnstert.2004.05.098.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeDoses of metforminObese womenOvary syndromeMenstrual frequencyMetformin treatmentHormone changesReproductive hormone changesMonths of treatmentCohort of folliclesUniversity Teaching HospitalOvarian responseOvarian functionTeaching hospitalMAIN OUTCOMEMIS concentrationsProspective treatmentSubstance levelsMetforminMonthsWomenAssessment periodTreatmentSyndromeDoses
2004
Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol
Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertility And Sterility 2004, 82: 1323-1329. PMID: 15533354, DOI: 10.1016/j.fertnstert.2004.03.061.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersEstradiolFemaleFertilization in VitroFollicle Stimulating HormoneGlycoproteinsHumansInhibinsMultivariate AnalysisOsmolar ConcentrationOvulation InductionPredictive Value of TestsPregnancyPregnancy RateRetrospective StudiesTesticular HormonesTime FactorsTreatment OutcomeConceptsReproductive technology outcomesMullerian-inhibiting substanceYears of ageMultivariate regression analysisInhibin BPregnancy outcomesIVF outcomesAntimullerian hormoneHigher clinical pregnancy rateSerum samplesAvailable serum markersDay 3 FSHSerum antimullerian hormoneClinical pregnancy rateClinical pregnancy outcomesInhibin B levelsFollicle-stimulating hormoneConsecutive serum samplesMüllerian-inhibiting substanceGreater prognostic valueTechnology outcomesRegression analysisClinical pregnancyOvarian stimulationOvulation induction
2002
Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles
Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden RM. Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertility And Sterility 2002, 77: 468-471. PMID: 11872196, DOI: 10.1016/s0015-0282(01)03201-0.Peer-Reviewed Original ResearchConceptsOvarian responseMIS concentrationsReproductive technology cyclesGreater serum concentrationsGroup of womenOvulation inductionSerum concentrationsMaximum serumRetrospective analysisMAIN OUTCOMESubstance levelsSerum MISSerum samplesMI levelsWomenMature oocytesTechnology cyclesReproductive technologiesOocytesSerumART programsGroupIVFGreater number
1993
Gonadotropin-releasing hormone agonist-induced differences in granulosa cell cycle kinetics are associated with alterations in follicular fluid müllerian-inhibiting substance and androgen content
Seifer DB, MacLaughlin DT, Penzias AS, Behrman HR, Asmundson L, Donahoe PK, Haning RV, Flynn SD. Gonadotropin-releasing hormone agonist-induced differences in granulosa cell cycle kinetics are associated with alterations in follicular fluid müllerian-inhibiting substance and androgen content. The Journal Of Clinical Endocrinology & Metabolism 1993, 76: 711-714. PMID: 8445031, DOI: 10.1210/jcem.76.3.8445031.Peer-Reviewed Original ResearchConceptsHuman menopausal gonadotropinCell cycle kineticsProliferative indexGranulosa cellsFollicular fluidControl groupCycle kineticsGnRH analogue leuprolideOvulation induction regimensFollicular fluid contentMüllerian-inhibiting substanceHuman granulosa cellsLuteinized granulosa cellsCI (3.2-3.6) PInduction regimensMenopausal gonadotropinOocyte retrievalAndrogen contentGnRHSpecific growth factorsFlow cytometryGrowth factorFolliclesFluid contentOne-way analysis